Connect with us

News

Brazil signs agreement for Bharat Biotech’s COVAXIN

Published

on

Bharat Biotech, India’s indigenous manufacturer of COVAXIN, has signed an agreement with Precisa Medicamentos, a private medical firm, for the supply of COVID vaccine to Brazil. According to the firm, the Brazilian government will directly procure the supplies as per the market requirement. Brazil is the second-worst hit COVID country with more than 8 million COVID cases and over 2,00,000 deaths.

The deal was finalized in the digital presence of André Aranha Corrêa do Lago, Brazil’s ambassador to India, between Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, and Precisa’s team. Emanuela Medrades, Director of Precisa, said, “Bharat Biotech has exceeded our expectations, demonstrating quality and safety at the level of the largest vaccine suppliers in the world.” A private plane will ship the batch of approved COVAXIN quantity to Brazil.

Experts suggest that the possibility of such a deal was under discussion ever since India announced the approval of COVAXIN’s emergency use along with Oxford’s CoviShield. Phase-II results of Bharat Biotech’s vaccine have been extremely promising as Drug Controller General of India (DGCI) gave the nod for the administration of COVAXIN to people who are more than 12 years old.

Along with the international participation, Bharat Biotech recently announced the delivery of its vaccine in 11 cities of India with each vial carrying 20 doses. Developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), these doses can be stored at 2 to 8 degrees Celsius.

Apart from the official order of 55 lakh doses in the first stage, the company has donated 16.5 lakh doses free of cost to the government. Mutual agreement between Bharat Biotech and the government has set the price of each dose at Rs 295.

The trust placed by international medical companies in Bharat Biotech’s COVAXIN makes a bold statement for the people maligning the image of the vaccine by doubting over its efficacy and expected results. Phase-III results, likely to be released in April, would put an end to such trivial debates.

Also Read

Analysing the Multiples-backed healthcare brand Vikram Hospital

 

Zomato Faces Backlash Over New Pure Veg Fleet: Embraces 'Red Reality'
Analysis2 days ago

Zomato Faces Backlash Over New Pure Veg Fleet: Embraces ‘Red Reality’

Apple Google AI Deal: 21st Century Tech Collab to Integrate Gemini-Like Features in iOS
Analysis2 days ago

Apple Google AI Deal: 21st Century Tech Collab to Integrate Gemini-Like Features in iOS
With this deal, Google will be able to tap into Apple’s 1.4 billion active user base worldwide and expand the reach of its AI, Gemini, to a new stratum of users.

The 'Paramount' Sale of Viacom18's 13.01% Stake to Reliance Establishes Mukesh Ambani as Asia's Media Mogul
Analysis2 weeks ago

The ‘Paramount’ Sale of Viacom18’s 13.01% Stake to Reliance Establishes Mukesh Ambani as Asia’s Media Mogul
Paramount Global has been aiming to improve its balance sheet after ending last financial year with a long-standing debt of $15 billion.

Adani-Qualcomm Meeting Sends Sparks Across the Indian Tech Ecosystem
Latest2 weeks ago

Adani-Qualcomm Meeting Sends Sparks Across the Indian Tech Ecosystem

91Club offers a unique blend of entertainment and monetary rewards, making it a preferred choice for 2 million players.
Latest3 weeks ago

91Club: The Gaming Platform To Earn Real Money
Play and Win: 91Club, Where Gaming Means Real Money

Daman Game is a platform offering many games designed to entertain players of all ages It offers you a chance to win money by playing games.
Latest3 weeks ago

Daman Game: Where Fun Meets Real Rewards
Game On with Daman: Where Entertainment Pays Off!

TATA's Tech Revolution: Venturing into Chipmaking
Analysis4 weeks ago

TATA’s Tech Revolution: Venturing into Chipmaking
TATA Prepares to Venture into Chipmaking Business: Becoming the Herald of Change and Development in the Indian Tech Ecosystem

BharatGPT’s Hanooman: Desi Artificial Intelligence Ready For March Public Launch
Latest4 weeks ago

BharatGPT’s Hanooman: Desi Artificial Intelligence Ready For March Public Launch
The Indian tech scene is about to witness a dramatic makeover as BharaGPT prepares the public launch of the ‘Made In India’ AI, Hanooman.

OpenAI Launches SORA, its Text-to-Video Generator Model
Latest1 month ago

OpenAI Launches SORA, its Text-to-Video Generator Model

Gully Labs Story
Latest2 months ago

How a Homegrown Indian Sneaker Brand, Gully Labs is Embracing Indianism
Gully Labs: Redefining the sneaker culture in India

Topics

Editor's Pick

0
Would love your thoughts, please comment.x
()
x